Novo Nordisk, with coffers filling with cash, buys rival to Bayer's kidney drug Kerendia in $1.3B deal

Novo Nordisk is putting its soaring semaglutide sales to work, agreeing to pay up to $1.3 billion for KBP Biosciences’ phase 3 challenger to Bayer’s chronic kidney disease (CKD) drug Kerendia.